Literature DB >> 27458712

Outbreak of pulmonary Pseudomonas aeruginosa and Stenotrophomonas maltophilia infections related to contaminated bronchoscope suction valves, Lyon, France, 2014.

Marine Guy1, Philippe Vanhems, Cédric Dananché, Michel Perraud, Anne Regard, Monique Hulin, Olivier Dauwalder, Xavier Bertrand, Jullien Crozon-Clauzel, Bernard Floccard, Laurent Argaud, Pierre Cassier, Thomas Bénet.   

Abstract

In April 2014, pulmonary Pseudomonas aeruginosa and Stenotrophomonas maltophilia co-infections potentially related to bronchoscopic procedures were identified in the intensive care units of a university hospital in Lyon, France. A retrospective cohort of 157 patients exposed to bronchoscopes from 1 December 2013 to 17 June 2014 was analysed. Environmental samples of suspected endoscopes were cultured. Bronchoscope disinfection was reviewed. Ten cases of pulmonary P. aeruginosa/S. maltophilia co-infections were identified, including two patients with secondary pneumonia. Eight cases were linked to bronchoscope A1 and two to bronchoscope A2. Cultures deriving from suction valves were positive for P. aeruginosa/S. maltophilia. Exposure to bronchoscopes A1 and A2 was independently coupled with increased risk of co-infection (adjusted odds ratio (aOR) = 84.6; 95% confidence interval (CI): 9.3-771.6 and aOR = 11.8, 95% CI: 1.2-121.3). Isolates from suction valves and clinical samples presented identical pulsotypes. The audit detected deficiencies in endoscope disinfection. No further cases occurred after discontinuation of the implicated bronchoscopes and change in cleaning procedures. This outbreak of pulmonary P. aeruginosa/S. maltophilia co-infections was caused by suction valve contamination of two bronchoscopes of the same manufacturer. Our findings underscore the need to test suction valves, in addition to bronchoscope channels, for routine detection of bacteria. This article is copyright of The Authors, 2016.

Entities:  

Keywords:  Pseudomonas aeruginosa; Stenotrophomonas maltophilia; bronchoscope; outbreak; pulmonary infection; suction valve contamination

Mesh:

Year:  2016        PMID: 27458712     DOI: 10.2807/1560-7917.ES.2016.21.28.30286

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  6 in total

1.  Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model.

Authors:  Iris H Chen; James M Kidd; Kamilia Abdelraouf; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

2.  Correlation Between the Number of Fiberoptic Bronchoscopies and Nosocomial Infection/Colonization of Carbapenem-Resistant Enterobacteriaceae.

Authors:  Wei-Hua Wang; Ying-Hong Wu; Yi-Min Wang; Chun-Lei Wang; Yun Liu; Peng Gao; Xiao-Jing Wu; Jiao-Qian Ying
Journal:  Infect Drug Resist       Date:  2022-06-20       Impact factor: 4.177

Review 3.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

4.  Stenotrophomonas maltophilia: An Emerging Pathogen of the Respiratory Tract.

Authors:  Tejaswi Kanderi; Isha Shrimanker; Qurat Mansoora; Kajol Shah; Anna Yumen; Saketram Komanduri
Journal:  Am J Case Rep       Date:  2020-05-25

5.  A systematic review and cost effectiveness analysis of reusable vs. single-use flexible bronchoscopes.

Authors:  J M Mouritsen; L Ehlers; J Kovaleva; I Ahmad; K El-Boghdadly
Journal:  Anaesthesia       Date:  2019-11-08       Impact factor: 6.955

Review 6.  What Healthcare Workers Should Know about Environmental Bacterial Contamination in the Intensive Care Unit.

Authors:  Vincenzo Russotto; Andrea Cortegiani; Teresa Fasciana; Pasquale Iozzo; Santi Maurizio Raineri; Cesare Gregoretti; Anna Giammanco; Antonino Giarratano
Journal:  Biomed Res Int       Date:  2017-10-29       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.